Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$3.44 +2.7%	$3.07	$2.07 ▼ $4.20	$110.81M	0.39	105,955 shs	82,598 shs
EXOZ eXoZymes	$9.25	$12.16	$8.50 ▼ $23.99	$77.40M	N/A	11,602 shs	1,872 shs
MGNX MacroGenics	$1.48 -3.9%	$1.48	$0.99 ▼ $5.77	$93.37M	1.59	837,104 shs	381,878 shs
PASG Passage Bio	$5.56 -3.6%	$7.55	$5.14 ▼ $26.60	$17.35M	1.67	21,706 shs	85,521 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	0.00%	+9.55%	-3.10%	+26.47%	+9.21%
EXOZ eXoZymes	0.00%	-5.71%	-25.10%	-14.67%	+924,999,900.00%
MGNX MacroGenics	0.00%	-8.07%	+8.03%	+17.46%	-71.04%
PASG Passage Bio	0.00%	+1,286.88%	-28.81%	-15.76%	-70.40%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANIX Anixa Biosciences	3.095 of 5 stars	3.6	3.0	0.0	0.0	2.8	3.3	0.0
EXOZ eXoZymes	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	4.1014 of 5 stars	3.2	4.0	0.0	4.4	0.6	2.5	0.6
PASG Passage Bio	2.2848 of 5 stars	3.5	2.0	0.0	0.0	0.6	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIX Anixa Biosciences	3.25	Buy	$9.00	161.63% Upside
EXOZ eXoZymes	0.00	N/A	N/A	N/A
MGNX MacroGenics	2.40	Hold	$5.71	286.10% Upside
PASG Passage Bio	3.00	Buy	$150.00	2,597.84% Upside

Current Analyst Ratings Breakdown

Latest PASG, MGNX, EXOZ, and ANIX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/24/2025	PASG Passage Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$120.00
6/10/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/29/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/20/2025	MGNX MacroGenics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $3.00
5/14/2025	MGNX MacroGenics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$8.00 ➝ $3.00
5/14/2025	MGNX MacroGenics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$6.00 ➝ $5.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	$0.59 per share	N/A
EXOZ eXoZymes	$70K	1,106.04	N/A	N/A	$1.25 per share	7.40
MGNX MacroGenics	$149.96M	0.62	N/A	N/A	$1.85 per share	0.80
PASG Passage Bio	N/A	N/A	N/A	N/A	$19.84 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIX Anixa Biosciences	-$12.55M	-$0.38	N/A	∞	N/A	N/A	-68.17%	-60.38%	9/5/2025 (Estimated)
EXOZ eXoZymes	-$5.86M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	-$66.97M	-$0.89	N/A	N/A	N/A	-36.23%	-59.84%	-23.45%	8/5/2025 (Estimated)
PASG Passage Bio	-$64.77M	-$20.40	N/A	N/A	N/A	N/A	-93.59%	-59.65%	8/14/2025 (Estimated)

Latest PASG, MGNX, EXOZ, and ANIX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	PASG Passage Bio	-$0.20	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	MGNX MacroGenics	-$0.59	N/A	N/A	N/A	$28.06 million	N/A
6/3/2025	Q2 2025	ANIX Anixa Biosciences	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A
5/13/2025	Q1 2025	MGNX MacroGenics	-$0.61	-$0.65	-$0.04	-$0.65	$9.59 million	$13.19 million
5/13/2025	Q1 2025	PASG Passage Bio	-$4.80	-$5.00	-$0.20	-$0.25	N/A	N/A
5/12/2025	Q1 2025	EXOZ eXoZymes	N/A	-$0.22	N/A	-$0.22	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	N/A
EXOZ eXoZymes	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A
PASG Passage Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIX Anixa Biosciences	N/A	8.89	8.89
EXOZ eXoZymes	N/A	6.52	6.52
MGNX MacroGenics	N/A	3.28	3.11
PASG Passage Bio	N/A	3.74	3.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIX Anixa Biosciences	29.13%
EXOZ eXoZymes	N/A
MGNX MacroGenics	96.89%
PASG Passage Bio	53.48%

Insider Ownership

Company	Insider Ownership
ANIX Anixa Biosciences	25.30%
EXOZ eXoZymes	72.41%
MGNX MacroGenics	13.00%
PASG Passage Bio	5.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIX Anixa Biosciences	5	32.21 million	24.06 million	Optionable
EXOZ eXoZymes	29	8.37 million	2.31 million	N/A
MGNX MacroGenics	430	63.09 million	54.89 million	Optionable
PASG Passage Bio	130	3.12 million	2.96 million	Optionable

PASG, MGNX, EXOZ, and ANIX Headlines

Recent News About These Companies

Passage Bio Announces 1-for-20 Reverse Stock Split

July 10, 2025 | globenewswire.com

Passage Bio, Inc. (PASG) Income Statement - Yahoo Finance

July 1, 2025 | finance.yahoo.com

PASG Passage Bio, Inc. - Seeking Alpha

June 27, 2025 | seekingalpha.com

Passage Bio, Inc. (NASDAQ:PASG) Major Shareholder Orbimed Advisors Llc Sells 138,800 Shares

June 27, 2025 | insidertrades.com

Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update

June 23, 2025 | globenewswire.com

Passage Bio Reports Q1 2025 Financial Results and Highlights Progress in Gene Therapy Development

May 17, 2025 | msn.com

Passage Bio : résultat d'exploitation de -16,459 millions de dollars au premier trimestre

May 13, 2025 | zonebourse.comZ

PASSAGE BIO, INC. : Wedbush persiste à l'achat

May 13, 2025 | zonebourse.comZ

Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights

May 13, 2025 | globenewswire.com

Insider Selling: Passage Bio, Inc. (NASDAQ:PASG) Major Shareholder Sells 68,195 Shares of Stock

April 25, 2025 | insidertrades.com

Passage Bio, Inc. (NASDAQ:PASG) Major Shareholder Orbimed Advisors Llc Sells 77,090 Shares

April 18, 2025 | insidertrades.com

OrbiMed Advisors vend des actions de Passage Bio pour 49.704$

April 18, 2025 | fr.investing.com

L’action PASG atteint son plus bas niveau sur 52 semaines à 0,3$ face aux défis du marché

April 8, 2025 | fr.investing.com

L’action de Passage Bio chute à un plus bas de 52 semaines à 0,35$

March 31, 2025 | fr.investing.com

L'action Passage Bio chute à son plus bas niveau sur 52 semaines à 0,38$

March 14, 2025 | fr.investing.com

Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know

March 7, 2025 | zacks.com

PASSAGE BIO, INC. : Chardan Research reste à l'achat

March 5, 2025 | zonebourse.comZ

L’action Passage Bio chute à son plus bas niveau sur 52 semaines à 0,45$

March 5, 2025 | fr.investing.com

Passage Bio price target lowered to $6 from $7 at Chardan

March 5, 2025 | markets.businessinsider.com

Passage Bio publie ses résultats du quatrième trimestre et de l'année 2024.

March 4, 2025 | zonebourse.comZ

New MarketBeat Followers Over Time

Media Sentiment Over Time

PASG, MGNX, EXOZ, and ANIX Company Descriptions

Anixa Biosciences NASDAQ:ANIX

$3.44 +0.09 (+2.69%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$3.43 -0.01 (-0.29%)

As of 07/18/2025 07:56 PM Eastern

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

eXoZymes NASDAQ:EXOZ

$9.25 0.00 (0.00%)

As of 07/18/2025 10:13 AM Eastern

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.

MacroGenics NASDAQ:MGNX

$1.48 -0.06 (-3.90%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.48 +0.01 (+0.34%)

As of 07/18/2025 05:42 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Passage Bio NASDAQ:PASG

$5.56 -0.21 (-3.64%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$5.74 +0.18 (+3.24%)

As of 07/18/2025 05:12 PM Eastern

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other program for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time